{"text": ["Novartis'", "(NVS)", "NSCLC", "Drug", "Fails", "to", "Meet", "Primary", "Endpoint"], "created_at": "2021-03-09 15:10:03"}
{"text": ["Novartis'", "Canakinumab", "Fails", "To", "Improve", "Survival", "In", "Late-Stage", "Lung", "Cancer", "Trial"], "created_at": "2021-03-09 14:05:23"}
{"text": ["The", "Daily", "Biotech", "Pulse:", "Regulatory", "Setback", "For", "Acadia,", "Lilly", "Forges", "Diabetes", "Antibody", "Treatment", "Collaboration,", "Aytu's", "Positive", "COVID-19", "Data"], "created_at": "2021-03-09 13:08:24"}
{"text": ["Molecular", "Partners/Novartis's", "COVID-19", "Antiviral", "Therapy", "Shows", "Encouraging", "Action", "Early-Stage", "Study"], "created_at": "2021-03-09 11:30:26"}
{"text": ["Novartis", "provides", "update", "on", "Phase", "III", "study", "evaluating", "canakinumab", "(ACZ885)", "as", "second", "or", "third-line", "treatment", "in", "combination", "with", "chemotherapy", "in", "non-small", "cell", "lung", "cancer"], "created_at": "2021-03-09 06:00:00"}
